Desoxypipradrol

Coronary artery disease, Cardiac arrhythmias, Uncontrolled hypertension, Structural heart disease

Desoxypipradrol's potent norepinephrine and dopamine reuptake inhibition produces sustained sympathomimetic cardiovascular activation. Tachycardia was documented in 65% of the 34-patient Edinburgh emergency department cluster, with tachypnoea in 76%. The multi-day duration of action means cardiovascular stress persists far longer than with most stimulants. Pre-existing cardiovascular conditions face compounded risk from this prolonged sympathomimetic load.

Epilepsy, History of seizures

Potent stimulants can lower seizure threshold through neuronal hyperexcitability. No published seizure data specific to desoxypipradrol exist, but the mechanism is consistent with dopaminergic stimulant class risk. The multi-day duration of action extends the window of elevated seizure risk.

Schizophrenia, Schizoaffective disorder, Bipolar disorder with psychotic features

Desoxypipradrol produces hallucinations in 50% and paranoia in 21% of documented clinical presentations at intoxicating doses (Murray et al. 2012). Psychosis persists for 3-7 days, far exceeding typical stimulant psychosis duration. Individuals with psychotic spectrum disorders face extreme risk of prolonged psychotic episodes from sustained dopaminergic stimulation lasting days.

Chronic kidney disease, Renal insufficiency

Rhabdomyolysis occurred in 96% of the Edinburgh case series (Murray et al. 2012), releasing myoglobin that must be cleared by the kidneys. Pre-existing renal impairment dramatically reduces the capacity to handle this myoglobin load, increasing the risk of acute renal failure requiring dialysis.

Pregnancy, Breastfeeding

No reproductive toxicology data exist for desoxypipradrol. Sustained sympathomimetic stimulation lasting days poses risks to placental perfusion and fetal cardiovascular development. The compound's high lipophilicity suggests placental transfer is likely. This is a class-level inference from stimulant pharmacology, not substance-specific data.

Concurrent MAOI therapy, Within 14 days of MAOI discontinuation

Combining any potent catecholamine reuptake inhibitor with MAO inhibition creates risk of hypertensive crisis through synergistic catecholamine accumulation. No published data exist for the specific desoxypipradrol-MAOI combination, but the mechanism is well-established for the drug class (cocaine, methylphenidate). Desoxypipradrol's multi-day duration extends the danger window.